← Russell 3000 cross-section

CVS CVS HEALTH Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Consumer Disc

Scale

Market cap
$119.6bn
Revenue TTM
$415.1bn
Net income TTM
$4.9bn
Free cash flow
$11.8bn
Composite score
66.5
Sector rank
#101

Valuation

P / E
24.5
EV / EBITDA
8.2
EV / sales
0.3
FCF yield
9.83%
Earnings yield vs 10-yr
-0.64pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
1.2%
EBITDA margin
3.1%
ROE
6.1%
ROIC
12.6%
Revenue growth
7.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Summary of Consolidated Financial Results Commentary - Three Months Ended June 30, 2026 vs. 2025 Revenues • Total revenues increased $7.2 billion, or 7.3%, in the three months ended June 30, 2026 compared to the prior year driven by revenue growth across all operating segments. • Please see “Segment Analysis” later in this report for additional information about the revenues of the Company’s segments. Operating expenses • Operating expenses decreased $166 million, or 1.5%, in the three months ended June 30, 2026 compared to the prior year primarily due to the absence of $833 million in legacy litigation charges recorded in the prior year, partially offset by continued business investments an …CVS HEALTH Corp, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →